Gallant Therapeutics

Gallant is developing multiple types of allogeneic or “off-the-shelf” cellular therapies for use in many feline and canine diseases.

The allogeneic therapies are all regulated by the FDA Center for Veterinary Medicine (CVM). Gallant has five INADs open currently, and participates in the FDA CVM Veterinary Innovation Program (VIP) that helps to “fast track” innovative therapies in development.

Gallant uses various cells types depending on the indication being treated incuding, uterine-derived stromal cells, adipose-derived stromal cells and “primed” cell therapies that are treated with various factors to drive them toward specific effectiveness outcomes such as immunomodulation for example.

Gallant Allogeneic Therapy Pipeline

Gallant Therapeutics - Pipeline

Gallant Scientific Advisory Board

  • Dori Borjesson DVM, PhD, MPVM

    Dr. Borjesson has been Washington State University dean of the College of Veterinary Medicine since July 2020 after more than a decade at the University of California-Davis School of Veterinary Medicine, where she established herself as a respected pioneer and leader in the field of veterinary medicine. She served in various leadership roles at UC-Davis, including as chair of the Department of Pathology, Microbiology and Immunology; director of the Clinical Regenerative Medicine Laboratory; and inaugural director of the Veterinary Institute for Regenerative Cure. She specialized in adult-derived stem cell research and spent her last 12 years at UC-Davis examining how stem cells alter the immune system. A board-certified veterinary clinical pathologist, Dr. Borjesson and has more than 100 peer-reviewed publications. She holds two patents in mesenchymal stem cells and immunomodulation, and some of her recent research has focused on naturally occurring inflammatory bowel disease in dogs, chronic gingivostomatitis in cats and spinal cord injury in dogs She received the Zoetis Research Excellence award in 2014 for the exceptional quality and productivity of her research efforts in regenerative medicine with an emphasis on utilizing mesenchymal stem cells as a therapeutic option for both orthopedic injury (such as bone and tendon damage) and in immunomodulation.... Show more

    Dr. Boaz Arzi is a Professor of Dentistry and Oral surgery at the department of Surgical and Radiological Sciences, UC Davis School of Veterinary Medicine. Dr. Arzi completed the residency-training program in dentistry and oral surgery at the School of Veterinary Medicine and two years fellowship in the Department of Biomedical Engineering at UC Davis. He is a Diplomate of the American Veterinary Dental College (AVDC) and the European Veterinary Dental College(EVDC). Dr. Arzi is also a Founding Fellow of the AVDC in Oral and Maxillofacial Surgery. Dr. Arzi’s clinical and research focus is on oral maxillofacial disorders and regenerative solutions in dogs and cats. His lab also investigates TMJ disorders and treatments across species. Dr. Arzi is the director of the Veterinary Institute for Regenerative Cures (VIRC) at UC Davis. Ultimately, Dr. Arzi’s work is translational with the aim of One Health treatment modalities for both human and animal health.... Show more
  • Scott R. Burger, MD

    Scott R. Burger, MD, is the Principal of Advanced Cell and Gene Therapy, a consulting firm specializing in cell and gene therapy product development, manufacturing, and regulatory affairs. Dr. Burger has over 25 years of experience developing cell and gene therapy products and has consulted for over 100 industry and academic clients in North America, Europe, Asia, and Australia. He has directed or consulted on process development, manufacturing, and regulatory aspects of a wide range of cell therapy and gene therapy products, including CAR T-cells, gene-edited cells, dendritic cell vaccines, natural killer (NK) cells, and other immunotherapies, hematopoietic stem cells (HSCs) from bone marrow, blood, umbilical cord blood, and regenerative medicine products such as mesenchymal stem cells (MSCs), chondrocytes, pancreatic islet cells, and other somatic cell therapies.<br />Dr. Burger’s regulatory background includes numerous IND and IDE submissions and productive interactions with FDA-CBER Office of Tissues and Advanced Therapies (OTAT, formerly the Office of Cellular, Tissue and Gene Therapies, OCTGT). Dr. Burger is a member of several scientific advisory boards, and has served on the USP Cell, Gene and Tissue Therapies Expert Committee, the ISCT advisory board and ISCT committees on gene therapy, regulatory affairs, commercialization, and product/process development. A graduate of the University of Pennsylvania School of Medicine, Dr. Burger completed training in clinical pathology and transfusion medicine at Washington University in St. Louis. Prior to founding Advanced Cell & Gene Therapy in 2002, Dr. Burger was Vice-President for R&D at Merix Bioscience, and director of the University of Minnesota Cell Therapy Clinical Laboratory. Dr. Burger is author of over 200 scientific publications and presentations, and recipient of numerous honors and awards.... Show more
  • Benjamin Lewis

    Benjamin is an animal health visionary, proud pet parent, and former Olympic athlete. As Chief Strategy Officer of the One Health Company, Ben is committed to advancing cancer cures for dogs. Formerly, Ben was the co-founder and CEO of 4Vets, the largest B2B distributor of animal health products in Brazil. Ben also represented the United States in the 2004 Olympics in Athens, Greece, where he served as captain of the K4. Ben studied bioengineering at Dartmouth College where he was inducted in the Dartmouth Hall of Fame (Wearer of the Green). In addition, Ben studied veterinary medicine at the University of Pennsylvania School of Veterinary Medicine, and Health Care Management at the Wharton School of Business.... Show more
  • Shelly Zacharias, DVM, MS, VPM, BCMAS

    Clinical Advisor
    Dr. Zacharias brings ten years of multifunctional and clinical leadership experience in the field of stem cell therapy research and development plus 14 years as a clinical small animal veterinarian. She has extensive experience in the scientific development and business operations of a start-up biotech, led corporate efforts, R&D, clinical trials, and has considerable experience in regulatory compliance. In 2010, she co-founded a veterinary biotech company, Renovocyte, that made strides in stem cell therapy development in metabolic diseases in dogs and cats. In 2013, she was involved in the sale of the company to a global human medical company, Cook Group, Inc, where she remained an integral member of the executive leadership team as the Director of Veterinary Operations. At this time, she led the company into a partnership with a global animal health company where positive data was generated in continued stem cell studies in dogs and cats. In 2019, she was again involved in the acquisition of the veterinary stem cell R&D company by Gallant. Dr. Zacharias manages external professional relationships, interacts with medical doctors and veterinarians in a translational medicine aspect, and has experience conducting clinical trials. She was instrumental in the development of a new “off-the-shelf” cell therapy drug for metabolic disease which she has been working toward FDA approval. Shelly holds a Bachelor of Science in Biochemistry from Cameron University as well as a Master of Arts in Secondary Science Education and a Doctor of Veterinary Medicine from the Oklahoma State College of Veterinary Medicine. She holds a certification in veterinary practice management (VPM) from Purdue University and has completed graduate-level studies in endocrinology prior to veterinary school. In 2020, she will complete the board certification for a medial affairs specialist (ACMA).... Show more
  • Chad Maki, BVM&S

    Dr. Maki is a veterinarian with over 15 years of experience in stem cell research, including translational research in dogs and cats using stem cell therapies. Prior to joining Gallant, he served as Chief Medical Officer at VetCell Therapeutics, a company developing “off-the-shelf” adipose-derived stem cell therapies for pets. While there, he led a team to conduct numerous veterinary clinical trials studying the safety and efficacy of cellular therapies in conditions such as canine atopic dermatitis, canine osteoarthritis and feline chronic gingivostomatitis. He has authored numerous peer-reviewed scientific publications and has been an invited speaker at multiple veterinary conferences presenting clinical trial results and educating on patient management using cell therapies. He has remained active in veterinary practice, and utilizes stem cell therapy for a variety of indications. Dr. Maki advises Gallant on clinical development and regulatory matters. He completed his veterinary training (BVM&S) at The Royal Dick School of Veterinary Studies at the University of Edinburgh, and obtained his bachelor of science (BS) degree from UC Berkeley.... Show more

Ready to learn more?

Explore our stem cell banking process or chat with one of our pet-loving experts.